FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Verbeke, Len ^a   Mannaerts, Inge ^b   Schierwagen, Robert ^c   Govaere, Olivier ^a   Klein, Sabine ^c   Vander Elst, Ingrid ^a   Windmolders, Petra ^a   Farre, Ricard ^d,e   Wenes, Mathias ^f,g   Mazzone, Massimiliano ^f,g   Nevens, Frederik ^a   Van Grunsven, Leo A ^b   Trebicka, Jonel ^c   Laleman, Wim ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^c UNIVERSITY OF BONN   (Germany)

^d UNIVERSITY OF LEUVEN   (Belgium)

^e INSTITUTO DE SALUD CARLOS III   (Spain)

^f UNIVERSITY OF LEUVEN   (Belgium)

^g DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AUTACOID; BIOLOGICAL MARKER; CELL RECEPTOR; CHENODEOXYCHOLIC ACID; CYTOKINE; FARNESOID X-ACTIVATED RECEPTOR; I KAPPA B KINASE ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOPOLYSACCHARIDE; OBETICHOLIC ACID; THIOACETAMIDE; TUMOR NECROSIS FACTOR;

AGONISTS; ANALOGS AND DERIVATIVES; ANIMAL; APOPTOSIS; CELL CYCLE; CELL LINE; CELL PROLIFERATION; COMPLICATION; DISEASE MODEL; DRUG EFFECT; ENDOTHELIUM CELL; HEMODYNAMICS; HEPATIC STELLATE CELL; HUMAN; INFLAMMATION; KUPFFER CELL; LIVER; LIVER CELL; LIVER CIRRHOSIS; MALE; METABOLISM; MOUSE; PATHOLOGY; PATHOPHYSIOLOGY; PORTAL VEIN BLOOD PRESSURE; UPREGULATION; VASCULAR RESISTANCE; WISTAR RAT;

ANIMALS; APOPTOSIS; BIOMARKERS; CELL CYCLE; CELL LINE; CELL PROLIFERATION; CHENODEOXYCHOLIC ACID; CYTOKINES; DISEASE MODELS, ANIMAL; ENDOTHELIAL CELLS; HEMODYNAMICS; HEPATIC STELLATE CELLS; HEPATOCYTES; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; KUPFFER CELLS; LIPOPOLYSACCHARIDES; LIVER; LIVER CIRRHOSIS; MALE; MICE; NF-KAPPA B; NF-KAPPAB INHIBITOR ALPHA; PORTAL PRESSURE; RATS, WISTAR; RECEPTORS, CYTOPLASMIC AND NUCLEAR; THIOACETAMIDE; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION; VASCULAR RESISTANCE;

EID: 84988001263     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep33453     Document Type: Article

References (52)

1. Hernandez-Gea, V., Friedman, S. L. Pathogenesis of liver fibrosis. Annu Rev Pathol 6, 425-456 (2011).
2. Mederacke, I. et al. Fate tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its aetiology. Nat Commun 4, 2823 (2013).
3. Pinzani, M. et al. Expression of platelet-derived growth factor and its receptors in normal human liver and during active hepatic fibrogenesis. Am J Pathol 148, 785-800 (1996).
4. Laleman, W., Landeghem, L., Wilmer, A., Fevery, J., Nevens, F. Portal hypertension: from pathophysiology to clinical practice. Liver Int 25, 1079-1090 (2005).
5. Friedman, S. L. Evolving challenges in hepatic fibrosis. Nat Rev Gastroenterol Hepatol 7, 425-436 (2010).
6. Klein, S. et al. Atorvastatin inhibits proliferation and apoptosis, but induces senescence in hepatic myofibroblasts and thereby attenuates hepatic fibrosis in rats. Lab Invest 92, 1440-1450 (2012).
7. Trebicka, J. et al. Atorvastatin attenuates hepatic fibrosis in rats after bile duct ligation via decreased turnover of hepatic stellate cells. J Hepatol 53, 702-712 (2010).
8. Mannaerts, I. et al. Class II HDAC inhibition hampers hepatic stellate cell activation by induction of microRNA-29. PLoS One 8, e55786 (2013).
9. Zimmermann, H. W.,Tacke, F. In search of the magic bullet: can liver inflammation and fibrosis be reversed with medications? Expert Rev Gastroenterol Hepatol. 1-3 (2015).
10. Zhu, Y., Li, F., Guo, G. L. Tissue-specific function of farnesoid X receptor in liver and intestine. Pharmacol Res 63, 259-265 (2011).
11. Pellicciari, R. et al. 6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. J Med Chem 45, 3569-3572 (2002).
12. Fiorucci, S. et al. The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis. Gastroenterology 127, 1497-1512 (2004).
13. Wang, Y. D. et al. Farnesoid X receptor antagonizes nuclear factor kappaB in hepatic inflammatory response. Hepatology 48, 1632-1643 (2008).
14. Yang, F. et al. Spontaneous development of liver tumors in the absence of the bile acid receptor farnesoid X receptor. Cancer Res 67, 863-867 (2007).
15. Fickert, P. et al. Farnesoid X receptor critically determines the fibrotic response in mice but is expressed to a low extent in human hepatic stellate cells and periductal myofibroblasts. Am J Pathol 175, 2392-2405 (2009).
16. Verbeke, L. et al. Obeticholic acid, a farnesoid-X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats. Hepatology 59(6), 2286-2298 (2014).
17. Mencarelli, A. et al. The bile acid sensor farnesoid X receptor is a modulator of liver immunity in a rodent model of acute hepatitis. J Immunol 183, 6657-6666 (2009).
18. Gadaleta, R. M. et al. Activation of bile salt nuclear receptor FXR is repressed by pro-inflammatory cytokines activating NF-? B signaling in the intestine. Biochim Biophys Acta 1812, 851-858 (2011).
19. Laleman, W. et al. A stable model of cirrhotic portal hypertension in the rat: thioacetamide revisited. Eur J Clin Invest 36, 242-249 (2006).
20. Mannaerts, I. et al. Chronic administration of valproic acid inhibits activation of mouse hepatic stellate cells in vitro and in vivo. Hepatology 51, 603-614 (2010).
21. Mannaerts, I. et al. Gene expression profiling of early hepatic stellate cell activation reveals a role for Igfbp3 in cell migration. PLoS One 8, e84071 (2013).
22. Schroyen, B. et al. Leptin-mediated reactive oxygen species production does not significantly affect primary mouse hepatocyte functions in vitro. Eur J Gastroenterol Hepatol 24, 1370-1380 (2012).
23. Xu, L. et al. Human hepatic stellate cell lines, LX-1 and LX-2: new tools for analysis of hepatic fibrosis. Gut 54, 142-151 (2005).
24. Laleman, W. et al. Nitroflurbiprofen, a nitric oxide-releasing cyclooxygenase inhibitor, improves cirrhotic portal hypertension in rats. Gastroenterology 132, 709-719 (2007).
25. Inagaki, Y., Okazaki, I. Emerging insights into Transforming growth factor beta Smad signal in hepatic fibrogenesis. Gut 56, 284-292 (2007).
26. Elsharkawy, A. M., Mann, D. A. Nuclear factor-kappaB and the hepatic inflammation-fibrosis-cancer axis. Hepatology 46, 590-597 (2007).
27. S. L. Friedman, Mechanisms of hepatic fibrogenesis. Gastroenterology 134, 1655-1669 (2008).
28. N. K. Saxena et al. Concomitant activation of the JAK/STAT, PI3K/AKT, and ERK signaling is involved in leptin-mediated promotion of invasion and migration of hepatocellular carcinoma cells. Cancer Res 67, 2497-2507 (2007).
29. Tacke, F., Zimmermann, H. W. Macrophage heterogeneity in liver injury and fibrosis. J Hepatol 60, 1090-1096 (2014).
30. Wehr, A. et al. Chemokine receptor CXCR6-dependent hepatic NK T Cell accumulation promotes inflammation and liver fibrosis. J Immunol 190, 5226-5236 (2013).
31. Pradere, J. P. et al. Hepatic macrophages but not dendritic cells contribute to liver fibrosis by promoting the survival of activated hepatic stellate cells in mice. Hepatology 58, 1461-1473 (2013).
32. Lee, U. E., Friedman, S. L. Mechanisms of hepatic fibrogenesis. Best Pract Res Clin Gastroenterol 25, 195-206 (2011).
33. Cassiman, D., Libbrecht, L., Desmet, V., Denef, C., Roskams, T. Hepatic stellate cell/myofibroblast subpopulations in fibrotic human and rat livers. J Hepatol 36, 200-209 (2002).
34. Klein, S. et al. HSC-specific inhibition of Rho-kinase reduces portal pressure in cirrhotic rats without major systemic effects. J Hepatol 57, 1220-1227 (2012).
35. Wang, Y. et al. New insights into the antifibrotic effects of sorafenib on hepatic stellate cells and liver fibrosis. J Hepatol 53, 132-144 (2010).
36. Úbeda, M. et al. Obeticholic acid reduces bacterial translocation and inhibits intestinal inflammation in cirrhotic rats. J Hepatol 64, Epub (2016).
37. Gadaleta, R. M. et al. Farnesoid X receptor activation inhibits inflammation an d preserves the intestinal barrier in inflammatory bowel disease. Gut 60(4), 463-472 (2011).
38. Verbeke, L. et al. The FXR Agonist Obeticholic Acid Prevents Gut Barrier Dysfunction and Bacterial Translocation in Cholestatic Rats. Am J Pathol 185, 409-419 (2015).
39. Seki, E. et al. CCR2 promotes hepatic fibrosis in mice. Hepatology 50, 185-197 (2009).
40. Verbeke, L., Nevens, F., Laleman, W. Bench-to-beside review: acute-on-chronic liver failure-linking the gut, liver and systemic circulation. Crit Care 15, 233 (2011).
41. Murphy, F. R. et al. Inhibition of apoptosis of activated hepatic stellate cells by tissue inhibitor of metalloproteinase-1 is mediated via effects on matrix metalloproteinase inhibition: implications for reversibility of liver fibrosis. J Biol Chem 277, 11069-11076 (2002).
42. Indra, M. R., Karyono, S., Ratnawati, R., Malik, S. G. Quercetin suppresses inflammation by reducing ERK1/2 phosphorylation and NF kappa B activation in Leptin-induced Human Umbilical Vein Endothelial Cells (HUVECs). BMC Res Notes 6, 275 (2013).
43. Lv, P. et al. Reversal effect of thalidomide on established hepatic cirrhosis in rats via inhibition of nuclear factor-kappaB/inhibitor of nuclear factor-kappaB pathway. Arch Med Res 38, 15-27 (2007).
44. Adorini, L., Pruzanski, M., Shapiro, D. Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis. Drug Discov Today 17, 988-997 (2012).
45. Kirillova, I., Chaisson, M., Fausto, N. Tumor necrosis factor induces DNA replication in hepatic cells through nuclear factor kappaB activation. Cell Growth Differ 10, 819-828 (1999).
46. Watson, M. R. et al. NF-kappaB is a critical regulator of the survival of rodent and human hepatic myofibroblasts. J Hepatol 48, 589-597 (2008).
47. Oakley, F. et al. Inhibition of inhibitor of kappaB kinases stimulates hepatic stellate cell apoptosis and accelerated recovery from rat liver fibrosis. Gastroenterology 128, 108-120 (2005).
48. Jacobs, M. D., Harrison, S. C. Structure of an IkappaBalpha/NF-kappaB complex. Cell 95, 749-758 (1998).
49. Liedtke, C. et al. Experimental liver fibrosis research: update on animal models, legal issues and translational aspects. Fibrogenesis Tissue Repair 6, 19 (2013).
50. Weng, H. L. et al. Profibrogenic transforming growth factor-beta/activin receptor-like kinase 5 signaling via connective tissue growth factor expression in hepatocytes. Hepatology 46, 1257-1270 (2007).
51. Neuschwander-Tetri, B. A. et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 385, 956-965 (2015).
52. Hirschfield, G. M. et al. Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid. Gastroenterology 148, 751-761, e758 (2015).